Tiffany & Co. (NYSE: TIF), Hologic, Inc. (NASDAQ: HOLX), Taleo Corp. (NASDAQ: TLEO), OmniVision Technologies, Inc. (NASDAQ: OVTI), St. Jude Medical, Inc. (NYSE: STJ) and Salesforce.com (NYSE: CRM) had ratings on them reiterated by analysts.
Oppenheimer reiterated its "Outperform" rating on Tiffany & Co. (TIF).
Canaccord Genuity reiterated its "Buy" rating on Hologic, Inc. (HOLX).
JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Overweight" rating on Taleo Corp. (TLEO). They have a price target of $38.00 on the company.
Morgan Keegan reiterated its "Market Perform" rating on OmniVision Technologies, Inc. (OVTI).
Canaccord Genuity reiterated its "Hold" rating on St. Jude Medical, Inc. (STJ). They have a price target of $42.00 on the company.
Jefferies (NYSE:JEF) reiterated its "Buy" rating on Salesforce.com (CRM).
Thursday, December 1, 2011
Autodesk (ADSK) (TMH) (UA) (UNH) (CAKE) (CEDC) Ratings Reiterated
Autodesk (NASDAQ: ADSK), Team Health Holdings (NYSE: TMH), Under Armour, Inc. (NYSE: UA), UnitedHealth Group Inc. (NYSE: UNH), Cheesecake Factory (NASDAQ: CAKE) and Central European Distribution Corp. (NASDAQ: CEDC) had ratings on them reiterated by analysts.
Piper Jaffray (NYSE:PJC) reiterated its "Neutral" rating on Team Health Holdings (TMH). They have a price target of $21.00 on the company.
Sterne Agee reiterated its "Neutral" rating on Under Armour, Inc. (UA). They have a price target of $90.00 on the company.
JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Overweight" rating on UnitedHealth Group Inc. (UNH). They have a price target of $60.00 on the company.
Canaccord Genuity reiterated its "Buy" rating on Autodesk (ADSK). They have a price target of $44.00 on the company.
Morgan Stanley (NYSE:MS) reiterated its "Equal Weight" rating on Cheesecake Factory (CAKE).
Credit Suisse (NYSE:CS) reiterated its "Underperform" rating on Central European Distribution Corp. (CEDC).
Piper Jaffray (NYSE:PJC) reiterated its "Neutral" rating on Team Health Holdings (TMH). They have a price target of $21.00 on the company.
Sterne Agee reiterated its "Neutral" rating on Under Armour, Inc. (UA). They have a price target of $90.00 on the company.
JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Overweight" rating on UnitedHealth Group Inc. (UNH). They have a price target of $60.00 on the company.
Canaccord Genuity reiterated its "Buy" rating on Autodesk (ADSK). They have a price target of $44.00 on the company.
Morgan Stanley (NYSE:MS) reiterated its "Equal Weight" rating on Cheesecake Factory (CAKE).
Credit Suisse (NYSE:CS) reiterated its "Underperform" rating on Central European Distribution Corp. (CEDC).
Viacom (VIA-B) (BMRN) (UNH) (ADSK) (AMZN) (AVNR) Ratings Reiterated
Viacom (NASDAQ: VIA-B), Biomarin Pharma (NASDAQ: BMRN), UnitedHealth Group Inc. (NYSE: UNH), Autodesk (NASDAQ: ADSK), Amazon.com, Inc. (NASDAQ: AMZN) and Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) had ratings on them reiterated by analysts.
Nomura reiterated its "Buy" rating on Viacom (VIA-B).
Wedbush reiterated its "Neutral" rating on Biomarin Pharma (BMRN). They have a price target of $34.00 on the company.
Goldman Sachs (NYSE:GS) reiterated its "Neutral" rating on UnitedHealth Group Inc. (UNH). They have a price target of $56.00 on the company.
Bank of America (NYSE:BAC) reiterated its "Neutral" rating on Autodesk (ADSK). They have a price target of $38.00 on the company.
Nomura reiterated its "Neutral" rating on Amazon.com, Inc. (AMZN).
Canaccord Genuity reiterated its "Buy" rating on Avanir Pharmaceuticals Inc. (AVNR). They have a price target of $6.00 on the company.
Nomura reiterated its "Buy" rating on Viacom (VIA-B).
Wedbush reiterated its "Neutral" rating on Biomarin Pharma (BMRN). They have a price target of $34.00 on the company.
Goldman Sachs (NYSE:GS) reiterated its "Neutral" rating on UnitedHealth Group Inc. (UNH). They have a price target of $56.00 on the company.
Bank of America (NYSE:BAC) reiterated its "Neutral" rating on Autodesk (ADSK). They have a price target of $38.00 on the company.
Nomura reiterated its "Neutral" rating on Amazon.com, Inc. (AMZN).
Canaccord Genuity reiterated its "Buy" rating on Avanir Pharmaceuticals Inc. (AVNR). They have a price target of $6.00 on the company.
Subscribe to:
Posts (Atom)